Comparing supra-annular versus intra-annular self-expanding aortic valves in routine TAVR practice

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational, real‑world comparison of two self‑expanding transcatheter aortic valve platforms—the supra‑annular Evolut (Medtronic) and the intra‑annular Navitor (Abbott)—performed at a single tertiary center. The primary outcome is procedural success at one month using VARC‑3 criteria, with clinical, conduction, and echocardiographic follow‑up at six months to compare hemodynamics, pacemaker rates, and coronary access implications. Eligible patients are those suitable for TAVR with a self‑expandable device via femoral access; valve‑in‑valve procedures and unsuitable femoral access are excluded. The analysis will use routine clinical and imaging data to describe comparative performance in contemporary practice rather than randomize therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* all patients elligible for TAVR witn a self expandable device

Exclusion Criteria:

* femoral access not suitable
* valve in valve procedures

Where it's running

• University hopsital
  Montpellier, Occitanie, France Recruiting

Study contacts

• Study coordinator: Florence LECLERCQ, MD
• Email: f-leclercq@chu-montpellier.fr
• Phone: +33467336212

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pre-emptive LAVA-ECMO support for complex, high-risk TAVR

  The team will try pre-emptive left atrial veno-arterial ECMO to stabilize adults with severe aortic stenosis undergoing complex, high-risk TAVR who are unstable or at risk of instability.

  Recruiting at 2 sites Atlantic Health System · Detroit, Michigan and 1 other locations · NCT07309029

• Islet re-transplantation after prior graft failure in adults with type 1 diabetes

  This study looks at whether giving another islet transplant after a prior failed graft helps adults with type 1 diabetes who have severe swings in blood sugar.

  Recruiting University Hospital, Montpellier · Montpellier · NCT07666789

• Tissue models of systemic sclerosis using patient-derived iPSCs

  Researchers will create iPSC lines from people with systemic sclerosis, their healthy relatives, and test them across several cell types to see how the disease affects tissues in the lab.

  Recruiting University Hospital, Montpellier · Montpellier · NCT07650565

• L-dopa treatment for a CTNNB1-related neurodevelopmental disorder in children

  This study tests whether L-dopa can help children with a CTNNB1-related neurodevelopmental disorder who have dystonia.

  Recruiting University Hospital, Montpellier · Montpellier, Hérault · NCT07614126

• Exploratory look at brain blood flow and metabolism before and after removing unruptured AVMs

  This study tests brain perfusion and metabolism with PET imaging and neuropsychological tests in adults before and six months after surgical treatment for unruptured brain AVMs.

  Recruiting University Hospital, Montpellier · Montpellier, France · NCT07569887

• Immun4Cure Cohort of Autoimmune Diseases

  A long-term, 500-person database and biobank is being built to study autoimmune diseases like RA, SLE, and scleroderma, plus healthy adults, using deep profiling and regular follow-ups over five years.

  Recruiting University Hospital, Montpellier · Montpellier · NCT07515638

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.